6 news items
Annovis Announces New Publication in a Peer-Reviewed Journal
ANVS
21 May 24
pharmacokinetic behavior, identify which animal models most closely mimic human responses, and explore the potential clinical implications of these variations
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
ANVS
13 May 24
responsible for PD and AD. About Annovis Bio, Inc.Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. is a clinical
Annovis Bio CEO Outlines Next Steps in Alzheimer's Research After Mixed Phase II/III Trial Results
ANVS
6 May 24
this goal.
At Annovis, we hold rigorous science, open communication, and transparency seriously, and it is our responsibility to conduct a clinical
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
ANVS
6 May 24
rigorous science, open communication, and transparency seriously, and it is our responsibility to conduct a clinical study in conformance with FDA
Annovis Bio Announces Statistically Significant Phase II/III Data In Patients With Early Alzheimer's Disease; Efficacy In The CGIC Endpoint Was Not Reached Due To The Limited Number Of Patients And Short Trial Duration
ANVS
29 Apr 24
trial in biomarker-positive early AD patients.Buntanetap is an oral molecule that selectively binds to an iron-responsive element in the mRNA
ku77potyzngaw2ahzf50yict1uapf0bb5bpx68cjlimk3voi2
ANVS
2 Apr 24
career at KPMG in corporate tax and has since held roles of increasing responsibility at InVentiv Health, PQ Corporation and Potters Industries
- Prev
- 1
- Next